| 000 | 01584nam a2200433 i 4500 | ||
|---|---|---|---|
| 005 | 20250918172137.0 | ||
| 008 | 121227s2012 xxka 001 0 eng | ||
| 020 |
_a9781119967262 _cRM162.35 (PPUKM) _cRM157.91 (PPUKMPRA) |
||
| 039 | 9 |
_a201605061051 _bruzini _c201401151015 _dafifah _c201307241635 _dsue _c201307241548 _dsue _y12-27-2012 _zIzzati |
|
| 040 |
_dUKM _erda |
||
| 090 | _aQV771.O712 2012 9HUKM | ||
| 090 |
_aQV771 _b.O712p 2012 9HUKMPRA |
||
| 090 |
_aQV771 _b.O712 2012 9HUKM |
||
| 090 |
_aQV771 _b.O712p 2012 9 |
||
| 100 | 1 |
_aOrleans-Lindsay, Justina, _eauthor. |
|
| 245 | 1 | 0 |
_aPharmacovigilance medical writing : _ba good practice guide / _cJustina Orleans-Lindsay. |
| 264 | 1 |
_aChichester, West Sussex : _bWiley-Blackwell, _c2012. |
|
| 264 | 4 | _c©2012. | |
| 300 |
_axvi, 269 pages ; _c22 cm. |
||
| 336 |
_atext _2rdacontent |
||
| 337 |
_aunmediated _2rdamedia |
||
| 338 |
_avolume _2rdacarrier |
||
| 650 | 2 | _aWriting. | |
| 650 | 2 |
_aHealth Communication _xmethods. |
|
| 650 | 2 | _aPharmacoepidemiology. | |
| 650 | 2 | _aDrug monitoring. | |
| 650 | 2 |
_aPharmaceutical Preparations _xadverse effects. |
|
| 650 | 2 | _aProduct Surveillance, Postmarketing. | |
| 650 | 2 | _aPharmacorigilance. | |
| 907 |
_a.b1554848x _b2021-01-26 _c2019-11-12 |
||
| 942 |
_c01 _n0 _kQV771.O712 2012 9HUKM |
||
| 914 | _avtls003520673 | ||
| 990 | _aizzati/za/sue | ||
| 991 | _aJabatan Farmasi, PPUKM | ||
| 991 | _aJabatan Farmakologi, Pra Klinikal PPUKM | ||
| 991 | _aPerpustakaan Dr. Abdul Latiff, KKL | ||
| 998 |
_ad _ap _ah _b2012-01-12 _cm _da _feng _gxxk _y0 _z.b1554848x |
||
| 999 |
_c537801 _d537801 |
||